Skip to main content

Longboard Pharmaceuticals, Inc. (LBPH)

NASDAQ: LBPH · IEX Real-Time Price · USD
9.14 -0.01 (-0.11%)
Sep 24, 2021 4:00 PM EDT - Market closed
Market Cap157.35M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out13.59M
EPS (ttm)-3.23
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume7,234
Open9.05
Previous Close9.15
Day's Range9.00 - 9.15
52-Week Range7.39 - 18.95
Betan/a
Analystsn/a
Price Target31.00 (+239.2%)
Est. Earnings DateNov 8, 2021

About LBPH

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines for neurological diseases. Its products include LP352, a Phase I clinical trial product for the developmental and epileptic encephalopathies (DEEs) and refractory epilepsies; LP143, a product for amyotrophic lateral sclerosis and other neuroinflammatory disorders; and LP659, a product for multiple neuroinflammatory disorders. Longboard Pharmaceuticals, Inc. was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard ...

IndustryBiotechnology
IPO DateMar 12, 2021
Employees14
Stock ExchangeNASDAQ
Ticker SymbolLBPH
Full Company Profile

News

Longboard Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference on September 28, 2021

SAN DIEGO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurolo...

5 days ago - GlobeNewsWire

Longboard Pharmaceuticals Successfully Completes LP352 Multiple Ascending Dose Portion of Phase 1 Clinical Trial in H...

SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurolo...

2 weeks ago - GlobeNewsWire

Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences

SAN DIEGO, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurolog...

3 weeks ago - GlobeNewsWire

Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2021 Financial Results

SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurolog...

1 month ago - GlobeNewsWire

Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2021 Financial Results

SAN DIEGO, May 10, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, t...

4 months ago - GlobeNewsWire

Longboard Pharmaceuticals Announces Pricing of Initial Public Offering

SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases,...

6 months ago - GlobeNewsWire

Neurological disease biotech Longboard Pharmaceuticals files for an $86 million IPO

Longboard Pharmaceuticals, a phase 1 biotech formed by Arena Pharmaceuticals developing medicines for neurological diseases, filed on Friday with the SEC to raise up to $86 million in an initial public ...

7 months ago - NASDAQ

Longboard Pharmaceuticals IPO Registration Document (S-1)

Longboard Pharmaceuticals, Inc. has filed to go public with an IPO on the NASDAQ.

7 months ago - SEC